Literature DB >> 29225091

Gene expression profiling of the TRIM protein family reveals potential biomarkers for indicating tuberculosis status.

Yanqing Chen1, Shuhui Cao2, Yong Sun3, Chuanyou Li4.   

Abstract

Tripartite motif (TRIM) family proteins play important regulatory roles in innate immune responses, the dysregulation of which cause several infectious diseases. However, the role and function of TRIM family proteins during tuberculosis (TB) infection remains unclear. In this study, we employed real-time quantitative PCR to profile the transcript levels of 72 TRIM genes from a cohort of 5 active TB patients, 5 latent tuberculosis infection (LTBI) subjects, and 5 healthy controls (HCs) in an initial discovery phase. The notable TRIM genes were assessed by in vitro cell infection experiments and further validated in another independent cohort (36 active TB, 24 LTBI and 28 HCs). The receiver operating characteristic (ROC) was used to analyze the diagnostic power of these TRIM genes. Our results revealed that 20 TRIM genes were decreased in active TB compared to LTBI and HCs. In addition, TRIM4, 16, 27, 32, 35, 46, 47, 65 and 68 were further shown to be downregulated in Mycobacterium smegmatis-infected macrophages and were found to be closely correlated with infection time and initial bacteria loads. Furthermore, the ROC analyses showed that TRIM4, 27 and 65 all exhibited the highest areas under the curve (AUC) values of 1.00 in discriminating active TB from LTBI and HCs. Moreover, TRIM27 combined with TRIM32 for an improved AUC value of 0.81 in discriminating LTBI from HCs. These results suggest that TRIM gene dysregulation might be involved in the pathogenesis of TB and that these genes could serve as potential biomarkers for indicating TB status.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  Active tuberculosis; Biomarkers; Gene expression; Latent infection; TRIM family

Mesh:

Substances:

Year:  2017        PMID: 29225091     DOI: 10.1016/j.micpath.2017.12.008

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  7 in total

Review 1.  Bag it, tag it: ubiquitin ligases and host resistance to Mycobacterium tuberculosis.

Authors:  Priscila C Campos; Danielle T Cunha; Luiz P Souza-Costa; Michael U Shiloh; Luis H Franco
Journal:  Trends Microbiol       Date:  2022-04-29       Impact factor: 18.230

2.  TRIM15 Exerts Anti-Tumor Effects Through Suppressing Cancer Cell Invasion in Gastric Adenocarcinoma.

Authors:  Weilin Chen; Chuanhui Lu; Jianming Hong
Journal:  Med Sci Monit       Date:  2018-11-09

Review 3.  Regulation of Tripartite Motif-Containing Proteins on Immune Response and Viral Evasion.

Authors:  Xiu-Zhong Zhang; Fu-Huang Li; Xiao-Jia Wang
Journal:  Front Microbiol       Date:  2021-12-01       Impact factor: 5.640

4.  Characterisation of secretome-based immune responses of human leukocytes infected with various Mycobacterium tuberculosis lineages.

Authors:  Benjawan Kaewseekhao; Sittiruk Roytrakul; Yodying Yingchutrakul; Marut Laohaviroj; Kanin Salao; Kiatichai Faksri
Journal:  PeerJ       Date:  2021-06-03       Impact factor: 2.984

Review 5.  Emerging Roles of MHC Class I Region-Encoded E3 Ubiquitin Ligases in Innate Immunity.

Authors:  Xiuzhi Jia; Chunyuan Zhao; Wei Zhao
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

6.  Mycolicibacterium smegmatis, Basonym Mycobacterium smegmatis, Expresses Morphological Phenotypes Much More Similar to Escherichia coli Than Mycobacterium tuberculosis in Quantitative Structome Analysis and CryoTEM Examination.

Authors:  Hiroyuki Yamada; Masashi Yamaguchi; Yuriko Igarashi; Kinuyo Chikamatsu; Akio Aono; Yoshiro Murase; Yuta Morishige; Akiko Takaki; Hiroji Chibana; Satoshi Mitarai
Journal:  Front Microbiol       Date:  2018-09-11       Impact factor: 5.640

7.  Identification of key genes and pathways for melanoma in the TRIM family.

Authors:  YiJun Xia; Jun Zhao; Chunjun Yang
Journal:  Cancer Med       Date:  2020-10-28       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.